Poliosis circumscripta in the acquired intradermal nevus on the scalp: a brief review on the pathogenesis of this phenomenon

gangrenosum’’ by Brunsting, Goeckerman and O’Leary, October 1930. Commentary: Pyoderma gangrenosum. Arch Dermatol 1982; 118: 743–773. 3 Reddick CL, Singh MN, Chalmers RJ. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. Dermatol Online J 2010; 16: 15. 4 Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007; 33: 787–802. 5 Marzano AV, Trevisan V, Lazzari R, Crosti C. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatolog Treat 2010; 21: 140–143. 6 Alexis AF, Strober BE. Off-label dermatologic uses of antiTNF-a therapies. J Cutan Med Surg 2005; 9: 296–302. 7 Tan MH, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137: 930–933. 8 Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double-blind, placebo-controlled trial. Gut 2006; 55: 505–509. 9 Pastor N, Betlloch I, Pascual JC, et al. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol 2006; 31: 152–153. 10 Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006; 5: e8.